

RECEIVED

MAY 0 2 2002

TECH CENTER 1600/2900

Applicants: Xu et al.

Application No.: 10/054,387

Filed: January 22, 2002

Title:

MHC CLASS II ANTIGEN PRESENTING CELLS CONTAINING

OLIGONUCLEOTIDES WHICH INHIBIT II PROTEIN EXPRESSION

UNITED STATES PATENT AND TRADEMARK OFFICE

07/3



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

KEVIN M. FARRELL, P.C.

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

[X] under 37 CFR 1.97(b), or

(Filed within three months of filing national application; within three months of date of entry of national stage of international application; or before mailing date of first office action on the merits; whichever occurs last)

[] under 37 CFR 1.97(c) together with either:
 [] a Certification under 37 CFR 1.97(e), or
 [] a \$240.00 fee under 37 CFR 1.17(p), or

(Filed after the CFR 1.97(b) time period, but before final action or notice of allowance)

[]	<pre>under 37 CFR 1.97(d) together with: [] a Certification under 37 CFR 1.97(e), and [] a petition under 37 CFR 1.97(d)(2)(ii), and [] a petition fee set forth in 37 CFR 1.17(i)(1).</pre>						
	(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)						
Method of Fee Payment:							
[]	Enclosed is a check in the amount of \$						
[]	Please charge Deposit Account 06-0130 in the amount of \$						
[]	Two duplicate copies of this Statement are enclosed.						
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 06-0130.						
Enclosed herewith is form PTO-1449:							
[]	Copies of the cited references are enclosed.						
[X]	Copies of cited references are enclosed except those of record in prior application, U.S. Serial No. 09/205,995, and references that are not required to be submitted under Rule 98.						
Concise Explanation Requirements:							
[]	The "concise explanation" requirement under C.F.R. 1.98(a)(3) is satisfied by:						
	[] the explanation provided on the attached sheet.						
	[] the explanation provided in the Specification.						
made	It is requested that the information disclosed herein be of record in this application.						
	Respectfully submitted,						
	were the second						

Kevin M. Farrell Attorney for Applicants Registration No. 35,505 (207) 363-0558

York Harbor ME Dated: 4\n\sqrt{n\sqrt{sqrt{p}}}

COPY OF PAPERS ORIGINALLY FILED

FORM PTO-1449 (REV. 7-80) •(REV. 7-80)

S. DEPARTMENT OF COMMERCE ATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO .: REH-2011

SERIAL NO.: 10/054,387 RECEIVED

TED BY APPLICANT

APPLICANTS: Xu et al.

MAY 0 2 2002

LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				FILING DATE: January 22, 2002	GROUP: TECH CENTER 160			
			U.S. PATI	ENT DOCUMENTS	. 		VENIEM	-1600/2 :
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING D	
	AA	5,726,020	10-Mar-98	Humphreys et al.				
	AB		•					
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
•	AK							
			FOREIGN PA	TENT DOCUMENTS	•			
		DOCUMENT NUMBER DATE COUNTRY CL		CLASS	SUB CLASS	TRANSLATION YES NO		
	AL							
	AM							
	AN							
	(OTHER ART (Includi	ng Author, T	itle, Date, Pertine	nt Pages	, Etc.)		
	AR	Bertolino et al.	, Crit. Revi	ews in Immunol. 16:	359-379	(1996).		
	AS	Ostrand-Rosenberg et al., <i>J. of Immunol.</i> 144: 4068-4071 (1990).						
	AT							
EXAMINER	1			DATE CONSIDERED				

RECEIVED ATTY. DOCKET NO.: SERIAL NO.: REH-2011 10/054,387 APPLICANTS: Xu et al. MAY 0 2 2002 GROUP: FILING DATE: January 22, 2002 TECH CENTER 1600/2900 U.S. PATENT DOCUMENTS SUB FILING DATE **EXAMINER** CLASS IF APPROPRIATE INITIAL CLASS NAME DOCUMENT NUMBER DATE OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Clements et al., J. of Immunol. 149: 2391-2396 (1992). AU Baskar et al., Cell. Immunol. 155: 123-133 (1994). ΑV Baskar et al., J. Exp. Med. 181: 619-629 (1995). AWArmstrong et al., Proc. Natl. Acad. Sci. USA 94: 6886-6891 (1997). AX Chen and Ananthaswamy, J. of Immunol. 151: 244-255 (1993). ΑY Moudgil et al., J. Immunol. 159: 2574-2579 (1997). ΑZ AR2 AS2 AT2 AU2

DATE CONSIDERED

REH\ARC\2011.449

EXAMINER